Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report published on Monday,RTT News reports. The firm currently has a $23.00 price target on the stock.

Several other brokerages have also issued reports on YMAB. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target on the stock. Finally, Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Y-mAbs Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $5.19 on Monday. The company has a market capitalization of $232.45 million, a PE ratio of -9.61 and a beta of 0.67. Y-mAbs Therapeutics has a one year low of $5.13 and a one year high of $19.12. The company’s fifty day moving average price is $6.58 and its 200 day moving average price is $10.72.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $44,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at $46,000. ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $99,000. Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics during the 3rd quarter worth about $133,000. Finally, Wells Fargo & Company MN grew its holdings in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after acquiring an additional 6,131 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.